Symcel announced that Jesper Ericsson has joined Symcel as Chief Executive Officer.
A newly-developed, fast, and cost-effective dipstick test sensitively and specifically identified Zika virus and all four dengue virus subtypes without any detectable cross-reactivity.
The Spanish biotech sector is growing. This attracts more and more international investors. End of September ASEBIO organised the first edition of an Investor Day.
German CRO Evotec AG announced an €15m investment in British Exscienta Ltd. to push artificial intelligence (AI)-driven drug discovery.
Danish Genmab A/S has received market approval in Japan for its anti-CD38 antibody daratumumab (DARZALEX®) as therapy for relapsed or refractory Multiple Myeloma.
Neurology specialist Newron Pharmaceuticals S.p.A. (Milan) has raised gross proceeds of CHF 27m through a private placement of new shares via an accelerated book-building process.
Though not reaching the overall surival endpoint in Phase III, the European Commission has granted label extension for Roches checkpoint blocker Tecentriq in two types of metastatic bladder cancer.
French microbiota specialist Da Volterra has received an EIB loan to speed up development of treatments that prevent antibiotic resistance and hospital acquired infections.
A team of US and German researchers has found that neutrophils secrete a regulatory RNA into lung tissue that protects against harmful inflammations.
Healthcare investor Vesalius Biocapital has created a new investment vehicle in collaboration with the Portuguese National Promotional bank (IFD) aimed at investing in Portuguese life science companies.